151 related articles for article (PubMed ID: 18563575)
1. Comparison of dissolution profiles for sustained release resinates of BCS class I drugs using USP apparatus 2 and 4: a technical note.
Prabhu NB; Marathe AS; Jain S; Singh PP; Sawant K; Rao L; Amin PD
AAPS PharmSciTech; 2008; 9(3):769-73. PubMed ID: 18563575
[No Abstract] [Full Text] [Related]
2. Is the full potential of the biopharmaceutics classification system reached?
Bergström CA; Andersson SB; Fagerberg JH; Ragnarsson G; Lindahl A
Eur J Pharm Sci; 2014 Jun; 57():224-31. PubMed ID: 24075971
[TBL] [Abstract][Full Text] [Related]
3. Biopharmaceutics classification systems for new molecular entities (BCS-NMEs) and marketed drugs (BCS-MD): theoretical basis and practical examples.
Papadopoulou V; Valsami G; Dokoumetzidis A; Macheras P
Int J Pharm; 2008 Sep; 361(1-2):70-7. PubMed ID: 18614303
[TBL] [Abstract][Full Text] [Related]
4. A non-binary biopharmaceutical classification of drugs: the ABΓ system.
Macheras P; Karalis V
Int J Pharm; 2014 Apr; 464(1-2):85-90. PubMed ID: 24456673
[TBL] [Abstract][Full Text] [Related]
5. Very rapid dissolution is not needed to guarantee bioequivalence for biopharmaceutics classification system (BCS) I drugs.
Kortejärvi H; Shawahna R; Koski A; Malkki J; Ojala K; Yliperttula M
J Pharm Sci; 2010 Feb; 99(2):621-5. PubMed ID: 19844950
[TBL] [Abstract][Full Text] [Related]
6. Ion Exchange Resins Transforming Drug Delivery Systems.
Gupta S; Benien P; Sahoo PK
Curr Drug Deliv; 2010 Jul; 7(3):252-62. PubMed ID: 20497105
[TBL] [Abstract][Full Text] [Related]
7. A comparative analysis of biopharmaceutics classification system and biopharmaceutics drug disposition classification system: a cross-sectional survey with 500 bioequivalence studies.
Cristofoletti R; Chiann C; Dressman JB; Storpirtis S
J Pharm Sci; 2013 Sep; 102(9):3136-44. PubMed ID: 23580377
[TBL] [Abstract][Full Text] [Related]
8. Solubility Determination of Active Pharmaceutical Ingredients Which Have Been Recently Added to the List of Essential Medicines in the Context of the Biopharmaceutics Classification System-Biowaiver.
Plöger GF; Hofsäss MA; Dressman JB
J Pharm Sci; 2018 Jun; 107(6):1478-1488. PubMed ID: 29421214
[TBL] [Abstract][Full Text] [Related]
9. The developability classification system: application of biopharmaceutics concepts to formulation development.
Butler JM; Dressman JB
J Pharm Sci; 2010 Dec; 99(12):4940-54. PubMed ID: 20821390
[TBL] [Abstract][Full Text] [Related]
10. Elucidating the role of dose in the biopharmaceutics classification of drugs: the concepts of critical dose, effective in vivo solubility, and dose-dependent BCS.
Charkoftaki G; Dokoumetzidis A; Valsami G; Macheras P
Pharm Res; 2012 Nov; 29(11):3188-98. PubMed ID: 22760660
[TBL] [Abstract][Full Text] [Related]
11. Paediatric biopharmaceutics classification system: current status and future decisions.
Batchelor H;
Int J Pharm; 2014 Aug; 469(2):251-3. PubMed ID: 24602991
[TBL] [Abstract][Full Text] [Related]
12. A Refined Developability Classification System.
Rosenberger J; Butler J; Dressman J
J Pharm Sci; 2018 Aug; 107(8):2020-2032. PubMed ID: 29665381
[TBL] [Abstract][Full Text] [Related]
13. Comparison of statistical analysis and Bayesian Networks in the evaluation of dissolution performance of BCS Class II model drugs.
Wilson WI; Peng Y; Augsburger LL
J Pharm Sci; 2005 Dec; 94(12):2764-76. PubMed ID: 16258987
[TBL] [Abstract][Full Text] [Related]
14. The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development.
Benet LZ
J Pharm Sci; 2013 Jan; 102(1):34-42. PubMed ID: 23147500
[TBL] [Abstract][Full Text] [Related]
15. Evaluation and suggested improvements of the Biopharmaceutics Classification System (BCS).
Fagerholm U
J Pharm Pharmacol; 2007 Jun; 59(6):751-7. PubMed ID: 17637167
[TBL] [Abstract][Full Text] [Related]
16. Simulation-based comparison of Biopharmaceutics Classification System and drug structure.
Chen T; Wu T; Li N; Jiang Y; Yin H; Wu M
Pharmazie; 2020 Apr; 75(4):124-130. PubMed ID: 32295687
[No Abstract] [Full Text] [Related]
17. Scientific considerations concerning the EMA change in the definition of "dose" of the BCS-based biowaiver guideline and implications for bioequivalence.
Daousani C; Macheras P
Int J Pharm; 2015 Jan; 478(2):606-9. PubMed ID: 25437115
[TBL] [Abstract][Full Text] [Related]
18. A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system.
Dokoumetzidis A; Macheras P
Int J Pharm; 2006 Sep; 321(1-2):1-11. PubMed ID: 16920290
[TBL] [Abstract][Full Text] [Related]
19. Degrees of order: A comparison of nanocrystal and amorphous solids for poorly soluble drugs.
Peltonen L; Strachan CJ
Int J Pharm; 2020 Aug; 586():119492. PubMed ID: 32505579
[TBL] [Abstract][Full Text] [Related]
20. From drug delivery systems to drug release, dissolution, IVIVC, BCS, BDDCS, bioequivalence and biowaivers.
Karalis V; Magklara E; Shah VP; Macheras P
Pharm Res; 2010 Sep; 27(9):2018-29. PubMed ID: 20635193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
